You are one of the co-authors of "Report B44 - treatment of patients with severe asthma." What aspects of the drug program does this report address? What are the main conclusions that come out of it?
The report is mainly concerned with how the program operates and how it is funded. It's not about the profitability of the program, since hospitals generally don't operate for profit, but whether facilities are adding to the program.
Unfortunately, like all drug programs, it suffers from a number of organizational and bureaucratic barriers. Implementers of this program complain that the number of tasks, including those around the program, is very large. The program's eligibility criteria are also cited by clinical experts as insufficient, meaning that not all patients who need it can be included. Geographic dispersion indicates that some patients may have difficulty accessing the centers, as they are concentrated in large cities. Finally, cost-effectiveness, which...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
